These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8837356)

  • 41. Monoclonal antibody-specific immobilisation of erythrocyte antigens (MAIEA). A new technique to selectively determine antigenic sites on red cell membranes.
    Petty AC
    J Immunol Methods; 1993 May; 161(1):91-5. PubMed ID: 8486932
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular basis for the high-incidence antigens of the Kell blood group system.
    Lee S; Naime DS; Reid ME; Redman CM
    Transfusion; 1997; 37(11-12):1117-22. PubMed ID: 9426633
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of monoclonal antibodies reacting with Kell system antigens.
    Sonneborn HH; Ernst M
    Rev Fr Transfus Immunohematol; 1988 Apr; 31(2):411-5. PubMed ID: 3212323
    [No Abstract]   [Full Text] [Related]  

  • 44. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia.
    Weiner CP; Widness JA
    Am J Obstet Gynecol; 1996 Feb; 174(2):547-51. PubMed ID: 8623782
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibodies with specificities related to the Kell blood group system.
    Parsons SF; Judson PA; Spring FA; Mallinson G; Anstee DJ
    Rev Fr Transfus Immunohematol; 1988 Apr; 31(2):401-5. PubMed ID: 3212321
    [No Abstract]   [Full Text] [Related]  

  • 46. Summary report of laboratories studying monoclonal antibodies in the Kell blood group system.
    Marsh WL
    Rev Fr Transfus Immunohematol; 1988 Apr; 31(2):417-8. PubMed ID: 3212324
    [No Abstract]   [Full Text] [Related]  

  • 47. Application of the MAIEA assay to the Kell blood group system.
    Petty AC; Daniels GL; Tippett P
    Vox Sang; 1994; 66(3):216-24. PubMed ID: 7518625
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Kell related antibodies.
    Daniels G
    Rev Fr Transfus Immunohematol; 1988 Apr; 31(2):395-400. PubMed ID: 3212320
    [No Abstract]   [Full Text] [Related]  

  • 49. Percutaneous umbilical blood sampling in the management of Kell isoimmunization.
    Copel JA; Scioscia A; Grannum PA; Romero R; Reece EA; Hobbins JC
    Obstet Gynecol; 1986 Feb; 67(2):288-90. PubMed ID: 3945439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti Kell allo-antibody in a thalassaemic.
    Thakral B; Saluja K; Sharma RR; Marwaha N; Marwaha RK
    Indian J Pathol Microbiol; 2006 Jan; 49(1):37-9. PubMed ID: 16625974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Monoclonal antibodies to high-incidence Kell epitopes: characterization and application in automated screening of donor samples.
    Inglis G; Fraser RH; McTaggart S; Sheridan R; Forrest AH; Mitchell R
    Transfus Med; 1994 Sep; 4(3):209-12. PubMed ID: 7820228
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distribution of Kell phenotype among pregnant women in Sokoto, North Western Nigeria.
    Osaro E; Ladan MA; Zama I; Ahmed Y; Mairo H
    Pan Afr Med J; 2015; 21():301. PubMed ID: 26587150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Report on group 7 (Kell related) antibodies.
    Lubenko A; Gee S; Contreras M
    Rev Fr Transfus Immunohematol; 1988 Apr; 31(2):407-9. PubMed ID: 3212322
    [No Abstract]   [Full Text] [Related]  

  • 54. Alloimmunization against platelets, granulocytes and erythrocytes in multi-transfused patients in Iranian population.
    Younesi MR; Louni Aligoudarzi S; Bigdeli R; Lashgari M; Mazaheri H; Asgary V
    Transfus Apher Sci; 2016 Oct; 55(2):205-211. PubMed ID: 27318433
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isolation of Kell-active protein from the red cell membrane.
    Redman CM; Marsh WL; Mueller KA; Avellino GP; Johnson CL
    Transfusion; 1984; 24(2):176-8. PubMed ID: 6200970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Another Kell-related antibody, anti-K19.
    Sabo B; McCreary J; Stroup M; Smith DE; Weidner JG
    Vox Sang; 1979; 36(2):97-102. PubMed ID: 462900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The quantification of erythrocyte antigen sites with monoclonal antibodies.
    Merry AH; Thomson EE; Anstee DJ; Stratton F
    Immunology; 1984 Apr; 51(4):793-800. PubMed ID: 6200429
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Significance of an Alloantibody against the Kell Blood Group Glycoprotein.
    Mattaloni SM; Arnoni C; Céspedes R; Nonaka C; Trucco Boggione C; Luján Brajovich ME; Trejo A; Zani N; Biondi CS; Castilho L; Cotorruelo CM
    Transfus Med Hemother; 2017 Jan; 44(1):53-57. PubMed ID: 28275334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Another example of a KEL1 variant red cell phenotype due to a threonine to serine change at position 193 of Kell glycoprotein.
    Lee-Stroka H; Slezak SL; Adams S; Martin J; Robbins FM; Caruccio L; Byrne KM; Stroncek DF
    Transfusion; 2008 May; 48(5):925-9. PubMed ID: 18248571
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibodies associated with the Kell blood group system.
    Marsh WL; Johnson CL; Rabin BI
    Rev Fr Transfus Immunohematol; 1988 Apr; 31(2):383-9. PubMed ID: 3212318
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.